{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:45:36Z","timestamp":1793943936522,"version":"4.8.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020124","name":"Seagen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We explored the efficacy and safety of brentuximab vedotin, a chimeric anti-CD30 antibody drug conjugate, in patients with severe active diffuse cutaneous systemic sclerosis (dcSSc).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This phase II proof-of-concept, single centre, open-label, single arm, investigator-initiated trial included patients \u226518\u2009years, with dcSSc, modified Rodnan skin score (mRSS) \u226515 with &amp;lt;5\u2009years since the first non-Raynaud\u2019s symptom and\/or skin worsening despite immunosuppression who were treated with intravenous brentuximab vedotin 0.6\u2009mg\/kg q3 weeks for 45\u2009weeks. The primary end point was a decrease in mRSS of \u22658 points at 48\u2009weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eleven patients were treated with brentuximab vedotin, with nine completing the study. The mean mRSS reduction at week 48 was 11.3 (95% CI 6.9, 15.8; P\u2009=\u20090.001), meeting the primary end point in the intention to treat analysis (7\/11 had a decrease in mRSS \u22658). The % forced vital capacity increased by 7.8% (12.5). The Composite Response Index in dcSSc (CRISS) suggested a beneficial treatment effect (86% \u22650.6). Most adverse events were mild. No SAEs were attributed to brentuximab vedotin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In dcSSc, brentuximab vedotin improved skin and FVC without safety concerns. A placebo-controlled trial is warranted to corroborate these initial findings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>ClinicalTrials.gov, http:\/\/clinicaltrials.gov, NCT03198689.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae235","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T16:05:28Z","timestamp":1713888328000},"page":"1476-1481","source":"Crossref","is-referenced-by-count":15,"title":["Brentuximab vedotin for skin involvement in refractory diffuse cutaneous systemic sclerosis, an open-label trial"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7939-7837","authenticated-orcid":false,"given":"Andreu","family":"Fern\u00e1ndez-Codina","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Western University , London, ON,","place":["Canada"]},{"name":"Division of General Internal Medicine-Windsor Campus, Western University , London, ON,","place":["Canada"]},{"name":"Division of Systemic Autoimmune Diseases and Critical Care, Hospital Clinic de Barcelona , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Nevskaya","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Western University , London, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray","family":"Baron","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Jewish General Hospital, McGill University , Montreal, QC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7148-0767","authenticated-orcid":false,"given":"C Thomas","family":"Appleton","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Western University , London, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J","family":"Cecchini","sequence":"additional","affiliation":[{"name":"Division of Pathology, Western University , London, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Philip","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Western University , London, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"El-Shimy","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Western University , London, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Vanderhoek","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Western University , London, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iago","family":"Pinal-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Muscle Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases , Bethesda, MD,","place":["USA"]},{"name":"Department of Neurology, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1479-5302","authenticated-orcid":false,"given":"Janet E","family":"Pope","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Western University , London, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,23]]},"reference":[{"key":"2025030500183559400_keae235-B1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet (London, England)"},{"key":"2025030500183559400_keae235-B2","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/annrheumdis-2016-210503","article-title":"Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)","volume":"76","author":"Herrick","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025030500183559400_keae235-B3","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1002\/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q","article-title":"Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial","volume":"43","author":"Clements","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2025030500183559400_keae235-B4","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/art.40560","article-title":"Treatment algorithms for systemic sclerosis according to experts","volume":"70","author":"Fern\u00e1ndez-Codina","year":"2018","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"2025030500183559400_keae235-B5","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41584-022-00765-9","article-title":"Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need","volume":"18","author":"Herrick","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2025030500183559400_keae235-B6","first-page":"1751","article-title":"Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis","volume":"151","author":"Mavalia","year":"1997","journal-title":"Am J Pathol"},{"key":"2025030500183559400_keae235-B7","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1038\/bcj.2017.85","article-title":"Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions","volume":"7","author":"van der Weyden","year":"2017","journal-title":"Blood Cancer J"},{"key":"2025030500183559400_keae235-B8","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy","year":"2001","journal-title":"J Rheumatol"},{"key":"2025030500183559400_keae235-B9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5301\/jsrd.5000231","article-title":"Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis","volume":"2","author":"Khanna","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"2025030500183559400_keae235-B10","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","article-title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin\u2019s lymphoma: a phase 1, open-label, dose-escalation study","volume":"14","author":"Younes","year":"2013","journal-title":"Lancet Oncol"},{"key":"2025030500183559400_keae235-B11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/2397198319886496","article-title":"Patient-reported outcome instruments in clinical trials of systemic sclerosis","volume":"5","author":"Pauling","year":"2020","journal-title":"J scleroderma Relat Disord"},{"key":"2025030500183559400_keae235-B12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"key":"2025030500183559400_keae235-B13","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/art.1780401110","article-title":"The value of the health assessment questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time","volume":"40","author":"Steen","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2025030500183559400_keae235-B14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/rheumatology\/kex396","article-title":"Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis","volume":"57","author":"Arnold","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2025030500183559400_keae235-B15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/art.39501","article-title":"The American College of Rheumatology provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis","volume":"68","author":"Khanna","year":"2016","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"2025030500183559400_keae235-B16","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025030500183559400_keae235-B17","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1002\/art.30549","article-title":"Imatinib in active diffuse cutaneous systemic sclerosis: results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center","volume":"63","author":"Pope","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2025030500183559400_keae235-B18","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.bbmt.2018.01.020","article-title":"Autologous hematopoietic stem cell transplantation for systemic sclerosis: a systematic review and meta-analysis","volume":"24","author":"Shouval","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025030500183559400_keae235-B19","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2014-03-561878","article-title":"Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event","volume":"123","author":"Gandhi","year":"2014","journal-title":"Blood"},{"key":"2025030500183559400_keae235-B20","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/14740338.2016.1179277","article-title":"A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma","volume":"15","author":"Oak","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"2025030500183559400_keae235-B21","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus Placebo in Scleroderma Lung Disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"2025030500183559400_keae235-B22","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2025030500183559400_keae235-B23","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"2025030500183559400_keae235-B24","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","article-title":"A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma","volume":"44","author":"Pope","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2025030500183559400_keae235-B25","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/art.41294","article-title":"Safety and efficacy of lenabasum in a phase II, randomized, placebo-controlled trial in adults with systemic sclerosis","volume":"72","author":"Spiera","year":"2020","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae235\/57829852\/keae235.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/3\/1476\/57829852\/keae235.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/3\/1476\/57829852\/keae235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:21:12Z","timestamp":1741134072000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/3\/1476\/7656783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,4,23]]},"published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae235","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,4,23]]}}}